Snowball logo
logo
3003_logo

Hangzhou Tigermed Consulting

300347 SHE
¥55.32+¥1.62  (3.02%)
Estimate
P/E
60.8
EPS
0.91
Beta
0.405
Growth
Revenue, YoY
15.17%
Net income, YoY
-70.36%
FCF, YoY
78.37%
Forecast
P/E (FWD)
44.1
EPS (FWD)
1.256
Dividends
Dividend yield
0.23%
Annual payout
¥0.13
Next ex. div date
July 10, 27
Payout
33.96%
Div.growth, 5y
1.53%
Div.rating
About the company
Ticker
300347
ISIN
CNE100001KV8
Country
China
Sector (GICS)
Healthcare
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Frequently asked questions

What sector does Hangzhou Tigermed Consulting (300347) operate in?

Hangzhou Tigermed Consulting belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is Hangzhou Tigermed Consulting (300347) current stock price?

As of the latest data, Hangzhou Tigermed Consulting stock price is CN¥55.32, with a previous close of CN¥53.70. Hangzhou Tigermed Consulting gained CN¥1.62 in the last trading session, representing a 3.02% increase.

What is Hangzhou Tigermed Consulting (300347) current market capitalization?

Hangzhou Tigermed Consulting market cap is approximately 40.82 billion.

What is Hangzhou Tigermed Consulting (300347) Earnings Per Share (EPS)?

The trailing EPS is CN¥0.91, and the forward EPS is CN¥1.26.

What is Hangzhou Tigermed Consulting (300347) Price-to-Earnings (P/E) ratio?

Hangzhou Tigermed Consulting current P/E ratio is 60.79, with a forward P/E of 44.05.

Does Hangzhou Tigermed Consulting (300347) pay dividends?

Yes. Hangzhou Tigermed Consulting pays annual dividends with an annualized yield of 0.23% and an estimated annual payout of CN¥0.13 per share.

When is the next ex-dividend date for Hangzhou Tigermed Consulting (300347)?

The next ex-dividend date is scheduled for July 10, 2027.

How did Hangzhou Tigermed Consulting (300347) perform in its most recent earnings report?

In the last report (March 31, 2026), Hangzhou Tigermed Consulting posted an EPS surprise of -158.87% and a revenue surprise of -0.11%.

What is Hangzhou Tigermed Consulting (300347) beta (volatility) score?

Hangzhou Tigermed Consulting has a beta of 0.405, indicating lower volatility than the overall market.